文献速递细菌感染、耐药与抗菌药物

多粘菌素剂量调控多重耐药鲍曼不动杆菌耐药性的进化动态

Polymyxin dose tunes the evolutionary dynamics of resistance in multidrug-resistant Acinetobacter baumannii.
PubMed 文献 · Clin Microbiol Infect · 2022-03-10

本研究以18个多重耐药鲍曼不动杆菌AB5075种群为对象,用基于人体药代动力学的多粘菌素B浓度处理14天,并通过全种群测序追踪耐药亚群的遗传与群体动态。结果发现多粘菌素B临界阈值浓度(1 mg/L,即4×MIC):低于该阈值时低水平耐药反复出现但无突变固定且撤药后可逆,而≥4×MIC时驱动不可逆耐药,抗生素浓度越高分子进化速率越快。

要点

  • 多粘菌素B临界阈值浓度为1 mg/L(即4×MIC)。
  • 低于阈值时耐药可逆,≥4×MIC时耐药不可逆。
  • 耐药亚群常见突变基因为pmrB、ompA、glmU/glmS和wecB/wecC。

核心结论

  • 多粘菌素施加的选择压力强度调控种群内遗传变异的动态,导致耐药程度、代价和可逆性出现不同的进化结局。
  • 研究强调将进化发现整合到药代动力学/药效学中以优化患者抗生素使用具有关键作用。

研究设计与样本

  • 以18个多重耐药鲍曼不动杆菌AB5075种群为研究对象,用基于人体药代动力学的多粘菌素B浓度处理14天。
  • 采用时间分辨全种群测序追踪敏感和耐药亚群的遗传学与群体动态。

主要发现

  • 鉴定出多粘菌素B临界阈值浓度为1 mg/L(即4×MIC)。
  • 低于该阈值浓度时,低水平耐药反复出现,但无突变固定,且撤除抗生素后耐药逆转。
  • 在超MIC水平(≥4×MIC)的多粘菌素B下,驱动了不可逆耐药进化,抗生素浓度越高分子进化速率越快。
  • 耐药亚群携带多种基因突变,最常见为pmrB、ompA、glmU/glmS和wecB/wecC,这些突变参与膜重塑和鲍曼不动杆菌毒力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Evolutionary principles have informed the design of strategies that slow or prevent antibiotic resistance. However, how antibiotic treatment regimens shape the evolutionary dynamics of resistance mutations remains an open question. Here, we investigate varying concentrations of the last-resort polymyxins on the evolution of resistance in Acinetobacter baumannii. METHODS: Polymyxin resistance was measured in 18 multidrug-resistant A. baumannii AB5075 populations treated over 14 days with concentrations of polymyxin B informed by human pharmacokinetics. Time-resolved whole-population sequencing was conducted to track the genetics and population dynamics of susceptible and resistant subpopulations. RESULTS: A critical threshold concentration of polymyxin B (1 mg/L; i.e. 4 × MIC) was identified. Below this threshold concentration, low levels of resistance repeatedly evolved, but no mutations were fixed, and this resistance was reversed upon removal of the antibiotic. This contrasted with evolution at super-MIC levels (≥4 × MIC) of polymyxin B, which drove the evolution of irreversible resistance, with higher levels of antibiotic correlating with greater rates of molecular evolution. Polymyxin-resistant subpopulations carried mutations in a variety of genes, most commonly pmrB, ompA, glmU/glmS, and wecB/wecC, which contributed to membrane remodelling and virulence in A. baumannii. CONCLUSIONS: Our results show that the strength of the selective pressure applied by polymyxin tunes the dynamics of genetic variants within the population, leading to different evolutionary outcomes for the degree, cost and reversibility of resistance. Our study highlights the critical role of integrating evolutionary findings into pharmacokinetics/pharmacodynamics to optimise antibiotic use in patients.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Zhao J, Zhu Y, Lin YW, et al. Polymyxin dose tunes the evolutionary dynamics of resistance in multidrug-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2022. PMID: 35283314. doi:10.1016/j.cmi.2022.02.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。